Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02226770
Other study ID # 252/12
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 14, 2010
Est. completion date October 28, 2016

Study information

Verified date October 2021
Source Universität des Saarlandes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to measure heart-focused anxiety, general anxiety, depression, PTSD and quality of life as well as type D personality in patients with heart failure before and after the implantation of a cardioverter defibrillator (ICD) and/or assist device (AD).


Description:

In patients with heart failure and implantable Cardioverter Defibrillator (ICD) psychological comorbidities such as heart focused anxiety and depression often occur. These psychological factors may have negative effects on compliance as well as on the development of the cardiac disease and therefore on rehospitalization and mortality rates. A personality structure where negative affect is paired with social inhibition (the inability to communicate ones feelings to others) can often be found in patients with cardiovascular disease. This so-called type D personality is also associated with a worse prognosis. It is of interest whether, and if so in what way, the implantation of an ICD can affect the psychological well-being and through that the prognosis of the heart failure patient. The goal of this study is therefore to investigate the effect of ICD implantation on heart-focused anxiety, depression, possible traumatization and quality of life in patients with heart failure with consideration of a possible moderating effect of the type D personality. Furthermore, the impact of the above stated psychological factors on rehospitalization and mortality, as well as on frequency of shocks shall be examined. Vice versa, the frequency of shocks or the impact of being shocked at all on psychological factors is of interest.


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date October 28, 2016
Est. primary completion date October 28, 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - heart failure, indication for an implantable Cardioverter Defibrillator Exclusion Criteria: - psychosis; advanced dementia; drug abuse

Study Design


Related Conditions & MeSH terms

  • Heart Failure
  • Heart Failure Patients Before and After ICD Implantation

Intervention

Device:
Implantable Cardioverter Defibrillator (ICD)


Locations

Country Name City State
Germany Saarland University Hospital Homburg Saarland

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Saarland Friede Springer Herz Stiftung

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Extent of heart-focused anxiety before and change after ICD implantation Heart-focused anxiety is measured through the use of the Cardiac Anxiety Questionnaire. All questionnaires will be filled out at baseline (before device implantation) as well as 5, 12 and 24 months after implantation. From baseline before ICD implantation to 24 months after implantation
Primary Extent of general anxiety and depression before and change after ICD implantation General anxiety and depression are recorded with the Hospital Anxiety and Depression Scale.
All questionnaires will be filled out at baseline (before device implantation) as well as 5, 12 and 24 months after implantation.
From baseline before ICD implantation to 24 months after implantation
Primary Quality of life before and change after ICD implantation Quality of life is documented through the Minnesota Living With Heart Failure Questionnaire.
All questionnaires will be filled out at baseline (before device implantation) as well as 5, 12 and 24 months after implantation.
From baseline before ICD implantation to 24 months after implantation
Primary Number of patients affected by PTSD before and after ICD implantation The Impact of Event Scale (revised) is used to evaluate the possibility of a post-traumatic stress disorder (PTSD).
All questionnaires will be filled out at baseline (before device implantation) as well as 5, 12 and 24 months after implantation.
From baseline before ICD implantation to 24 months after implantation
Secondary Impact of type D personality on heart-focused anxiety Type D ist measured with the Type D Scale-14 (DS14). Heart-focused anxiety is measured as stated in the primary outcome measures section. For type D: Baseline and for the psychological variable: from baseline before ICD implantation to 24 months after implantation
Secondary Impact of type D personality on general anxiety and depression Type D ist measured with the DS14. General anxiety and depression are measured as stated in the primary outcome measures section. For type D: Baseline and for the psychological variables: from baseline before ICD implantation to 24 months after implantation.
Secondary Impact of type D personality on quality of life. Type D ist measured with the DS14. Quality of life is measured as stated in the primary outcome measures section. For type D: Baseline and for the psychological variable: from baseline before ICD implantation to 24 months after implantation.
Secondary Impact of type D personality on PTSD. Type D ist measured with the DS14. PTSD is measured as stated in the primary outcome measures section. For type D: Baseline and for the psychological variable: from baseline before ICD implantation to 24 months after implantation.
Secondary Impact of type D personality on numbers of shocks. Type D ist measured with the DS14. ICD-shocks will be measured as number of shocks per patient. For type D: Baseline and for number of shocks: from ICD implantation to 24 months after implantation.
Secondary Impact of type D Personality on rehospitalization and morbidity. Type D ist measured with the DS14. Psychological factors will be measured as stated in the primary outcomes section.
Rehospitalization will be measured as number of times of readmission and mortality will be measured in total numbers of patients.
For type D: Baseline and for rehospitalization and morbidity: from implantation until 24 months after implantation..
Secondary Influence of heart-focused anxiety on rehospitalization and morbidity Heart-focused anxiety will be measured as stated in the primary outcomes section.
Rehospitalization will be measured as number of times of readmission and mortality will be measured in total numbers of patients.
Baseline to 24 months after implantation.
Secondary Influence of general anxiety and depression in rehospitalization and morbidity General anxiety and depression will be measured as stated in the primary outcomes section.
Rehospitalization will be measured as number of times of readmission and mortality will be measured in total numbers of patients.
Baseline to 24 months after implantation.
Secondary Influence of quality of life on rehospitalization and morbidity Quality of life will be measured as stated in the primary outcomes section. Rehospitalization will be measured as number of times of readmission and mortality will be measured in total numbers of patients. Baseline to 24 months after implantation.
Secondary Effect of ICD-shocks on heart-focused anxiety and effect of heart-focused anxiety on frequency of shocks Heart-focused anxiety will be measured as stated in the primary outcomes section.
ICD-shocks will be measured as number of shocks per patient.
Baseline to 24 months after implantation.
Secondary Effect of ICD-shocks on general anxiety and depression and effect of general anxiety and depression on frequency of shocks General anxiety and depression will be measured as stated in the primary outcomes section.
ICD-shocks will be measured as number of shocks per patient.
Baseline to 24 months after implantation.
Secondary Effect of ICD-shocks on quality of life and effect of quality of life on frequency of shocks Quality of life will be measured as stated in the primary outcomes section. ICD-shocks will be measured as number of shocks per patient. Baseline to 24 months after implantation.